{"name":"Tianjin Hemay Pharmaceutical Co., Ltd","slug":"tianjin-hemay-pharmaceutical-co-ltd","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"Hemay808","genericName":"Hemay808","slug":"hemay808","indication":"Other","status":"phase_2"},{"name":"Hemay022","genericName":"Hemay022","slug":"hemay022","indication":"Other","status":"phase_1"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"immunology","drugs":[{"name":"Hemay022+AI","genericName":"Hemay022+AI","slug":"hemay022-ai","indication":"Non-small cell lung cancer","status":"phase_3"},{"name":"Lapatinib+Capecitabine","genericName":"Lapatinib+Capecitabine","slug":"lapatinib-capecitabine","indication":"HER2-positive metastatic breast cancer","status":"phase_3"}]}],"pipeline":[{"name":"Hemay808","genericName":"Hemay808","slug":"hemay808","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Hemay022","genericName":"Hemay022","slug":"hemay022","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Hemay022+AI","genericName":"Hemay022+AI","slug":"hemay022-ai","phase":"phase_3","mechanism":"Hemay022+AI is an anti-PD-L1 monoclonal antibody combined with an AI-optimized therapeutic approach to enhance immune checkpoint inhibition and anti-tumor immunity.","indications":["Non-small cell lung cancer","Other solid tumors (specific indications under investigation in Phase 3)"],"catalyst":""},{"name":"Lapatinib+Capecitabine","genericName":"Lapatinib+Capecitabine","slug":"lapatinib-capecitabine","phase":"phase_3","mechanism":"Lapatinib inhibits HER2 and EGFR tyrosine kinases while capecitabine is a prodrug that converts to 5-fluorouracil to inhibit thymidylate synthase, together targeting HER2-positive breast cancer through dual mechanisms.","indications":["HER2-positive metastatic breast cancer","HER2-positive early-stage breast cancer (adjuvant/neoadjuvant setting)"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi6gFBVV95cUxPMGhPdGxVQ2ZhVEN3MkFUXy1rb0VSR3Y3Y3FuWXhzVWdMVmVkdkpHZnZXMWRHcnAyeEVUTVN0X09tRDA3bVdtR2M4M1lVNFo5UXNWWjEzRkNoSjBJS0llaXZNV0VSaEFqOFpvcjFoa0paYkNCZi1HdGR4OHBVY2Y4eGFTNWNLUzFkaHgydjNSRkxiNDdsU2c1WWl1elI0aUNfRmh2c0xYMENfZ0oteDk5c1hRY0swVjVkMjJaMF93eGpSaTBnVFJETjNxMFpSOUx0c1Z5N0VBdlFjYzlpNnhrcGxBbFAzZ20ycVE?oc=5","date":"2025-04-15","type":"pipeline","source":"prnewswire.com","summary":"Takeda's ENTYVIO Continues Growth Trajectory in Ulcerative Colitis and Crohn's Disease | DelveInsight - prnewswire.com","headline":"Takeda's ENTYVIO Continues Growth Trajectory in Ulcerative Colitis and Crohn's Disease | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwJBVV95cUxNMVBaRmxTUlZYYlVWSDVjcTktZFljZjFfcE9VbDlMR29mYUNmdGhENU1KMTRoVG1NcnVtUVphMnJuMXB0V0tCb1ZGVFZIOVFPMDBjQ3NNTC1ETWdnOFJGTy12Y2VJM1VLbDZzYlQ0bmlGRlhBb0Y0dlpPZ2hwb213TW01Z1RETzBBTU9vbFdtcjhaZHdMZERpbWlRQ0dCa2c1SVB2MXVkWjJrSXk5V0Z4Z1VneTlreEFEX0h2dW54NGpnRGt0a29fLW5xZEZoMDg4V0dDRGhvMDV1Q3hmQTlNcmJieVBmTEdoRXlvZ0hvcXdqbDdFazdMSGEwSU4yQkFGdVg4R1Nla3lXQ19hOUtwX0lJZVlBLTFVQkpF?oc=5","date":"2024-07-15","type":"regulatory","source":"prnewswire.com","summary":"SKYRIZI's Approval For Ulcerative Colitis Treatment Expands AbbVie's Portfolio Across Immune-mediated Inflammatory Diseases | DelveInsight - prnewswire.com","headline":"SKYRIZI's Approval For Ulcerative Colitis Treatment Expands AbbVie's Portfolio Across Immune-mediated Inflammatory Disea","sentiment":"positive"}],"patents":[],"drugCount":4,"phaseCounts":{"phase_2":1,"phase_1":1,"phase_3":2},"enrichmentLevel":0,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}